The ‘Hero of n-Lorem’ Award is a recognition given to an individual volunteer or organization that has made substantial contributions to n-Lorem and our nano-rare patients. This honor recognizes our ‘unsung heroes’, those who have gone the extra mile, taken time away from their schedules and families and leveraged their expertise and contacts to support n-Lorem’s mission to provide hope and potential help to nano-rare patients. On this episode of the Patient Empowerment Program podcast, we welcome three of our five 2025 Heroes for a conversation about their inspiration to take action:
- Wendy Erler, Senior Vice President, Patient Affairs, Sarepta Therapeutics
- Richard S. Geary, Ph.D., Chief Development Officer, Executive Vice President of Development, Ionis Pharmaceuticals
- Scott Henry, Ph.D., DABT, SVP, Nonclinical Development, Ionis Pharmaceuticals
 
 
Sponsors:
 
<a href='https://www.chemgenes.com/'>ChemGenes</a>
<a href='https://www.hongene.com/'>Hongene Biotech</a>
 
NRPC25: <a href='https://www.nlorem.org/nano-rare-patient-colloquium-2025/'>https://www.nlorem.org/nano-rare-patient-colloquium-2025/</a>

The ‘Hero of n-Lorem’ Award is a recognition given to an individual volunteer or organization that has made substantial contributions to n-Lorem and our nano-rare patients. This honor recognizes our ‘unsung heroes’, those who have gone the extra mile, taken time away from their schedules and families and leveraged their expertise and contacts to support n-Lorem’s mission to provide hope and potential help to nano-rare patients. On this episode of the Patient Empowerment Program podcast, we welcome three of our five 2025 Heroes for a conversation about their inspiration to take action: - Wendy Erler, Senior Vice President, Patient Affairs, Sarepta Therapeutics - Richard S. Geary, Ph.D., Chief Development Officer, Executive Vice President of Development, Ionis Pharmaceuticals - Scott Henry, Ph.D., DABT, SVP, Nonclinical Development, Ionis Pharmaceuticals Sponsors: ChemGenes Hongene Biotech NRPC25: https://www.nlorem.org/nano-rare-patient-colloquium-2025/

The ‘Hero of n-Lorem’ Award is a recognition given to an individual volunteer or organization that has made substantial contributions to n-Lorem and our nano-rare patients. This honor recognizes our ‘unsung heroes’, those who have gone the extra mile, taken time away from their schedules and families and leveraged their expertise and contacts to support n-Lorem’s mission to provide hope and potential help to nano-rare patients. On this episode of the Patient Empowerment Program podcast, we welcome three of our five 2025 Heroes for a conversation about their inspiration to take action:
- Wendy Erler, Senior Vice President, Patient Affairs, Sarepta Therapeutics
- Richard S. Geary, Ph.D., Chief Development Officer, Executive Vice President of Development, Ionis Pharmaceuticals
- Scott Henry, Ph.D., DABT, SVP, Nonclinical Development, Ionis Pharmaceuticals
&nbsp;
&nbsp;
Sponsors:
 
<a href="https://www.chemgenes.com/" rel="noopener noreferrer">ChemGenes</a>
<a href="https://www.hongene.com/" rel="noopener noreferrer">Hongene Biotech</a>
&nbsp;
NRPC25: <a href="https://www.nlorem.org/nano-rare-patient-colloquium-2025/" rel="noopener noreferrer">https://www.nlorem.org/nano-rare-patient-colloquium-2025/</a>&nbsp;
&nbsp;

A Conversation with the 2025 Heroes of n-Lorem

Join the nano-rare disease community! Interviews features leading physicians, scientists, biotech experts, and patient advocates. Lessons teach core concepts about drugs. Our host Dr. Crooke has led the creation of antisense technology and his foundation, n-Lorem, is using this powerful technology to discover, develop, and provide personalized experimental antisense oligonucleotide medicines to nano-rare patients for free, for life. 

n-Lorem is a non-profit organization established to apply the efficiency, versatility and specificity of antisense technology to charitably provide experimental antisense oligonucleotide (ASO) medicines to treat patients (less than 30 patients) that are the result of a single genetic defect unique to only one or very few individuals. The advantage of experimental ASO medicines is that they can be developed rapidly, inexpensively and are highly specific. n-Lorem was founded by Dr. Stan Crooke, who founded IONIS Pharmaceuticals in 1989 and, through his vision and leadership, established the company as the leader in RNA-targeted therapeutics. 

The podcast is produced by n-Lorem Foundation and hosted by Dr. Stanley T. Crroke, who is the Founder, CEO and Chairman. Our videographer is Jon Magnuson. Our producers are Kira Dineen, Jon Magnuson, Kim Butler, and Amy Williford. To learn more about n-Lorem, visit nlorem.org. Contact us at podcast@nlorem.org.

Science

Medicine

Health & Fitness

Education

Life Sciences

Join the nano-rare disease community! Interviews features leading physicians, scientists, biotech experts, and patient advocates. Lessons teach core concepts about drugs. Our host Dr. Crooke has led the creation of antisense technology and his foundation, n-Lorem, is using this powerful technology to discover, develop, and provide personalized experimental antisense oligonucleotide medicines to nano-rare patients for free, for life. n-Lorem is a non-profit organization established to apply the efficiency, versatility and specificity of antisense technology to charitably provide experimental antisense oligonucleotide (ASO) medicines to treat patients (less than 30 patients) that are the result of a single genetic defect unique to only one or very few individuals. The advantage of experimental ASO medicines is that they can be developed rapidly, inexpensively and are highly specific. n-Lorem was founded by Dr. Stan Crooke, who founded IONIS Pharmaceuticals in 1989 and, through his vision and leadership, established the company as the leader in RNA-targeted therapeutics. The podcast is produced by n-Lorem Foundation and hosted by Dr. Stanley T. Crroke, who is the Founder, CEO and Chairman. Our videographer is Jon Magnuson. Our producers are Kira Dineen, Jon Magnuson, Kim Butler, and Amy Williford. To learn more about n-Lorem, visit nlorem.org. Contact us at podcast@nlorem.org.

Share A Conversation with the 2025 Heroes of n-Lorem

Sign up to save your podcasts

A Conversation with the 2025 Heroes of n-Lorem

A Conversation with the 2025 Heroes of n-Lorem

More shows like Patient Empowerment Program: A Rare Disease Podcast

This American Life

Radiolab

The Daily

Crime Junkie

The Readout Loud

The Bulwark Podcast

The Happiness Lab with Dr. Laurie Santos

BioCentury This Week

The Mel Robbins Podcast

Fifteen: Inside the Daniel Marsh Murders